Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2022-04-04 Board/Management Inform…
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
Form 8-K - Director Appointment
Board/Management Information Classification · 99% confidence The document is explicitly titled "FORM 8-K" and is a "CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934." The content details an appointment of a new director under "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." A Form 8-K is a general current report used for material, unscheduled events. Among the provided specific codes, none perfectly match a general Form 8-K filing. However, the content specifically relates to changes in the Board of Directors (appointment of Mr. Yadin Rozov). This aligns most closely with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. While Form 8-K is the regulatory filing type, MANG captures the substantive nature of the disclosure in this specific item.
2022-04-04 English
Form 8-K - Director Appointment
Board/Management Information Classification · 95% confidence The document is an 'Immediate Report' filed under Israeli regulations, specifically referencing a 'Form 8-K - Director Appointment'. A Form 8-K is used in the US to report major events that shareholders should know about. The key content states: 'Attached hereto is a report on *Form 8-K - Director Appointment* *Oramed_Form_8-K_-_Yadin_Rozov_-_20220404.pdf*'. This indicates the document itself is an announcement *about* a director appointment, rather than the full management change report or a general regulatory filing. Since the document announces a change in senior management (Director Appointment), the most appropriate category is 'Board/Management Information' (MANG). Although it is an announcement, MANG is more specific than the general 'RPA' or 'RNS' for this type of corporate event disclosure.
2022-04-04 English
CURRENT REPORT
Regulatory Filings
2022-04-04 English
Form 10-Q/T fiscal year transition report
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q filed with the SEC by Oramed Pharmaceuticals Inc. It explicitly contains interim condensed consolidated financial statements, balance sheets, and management's discussion and analysis for a transition period. As it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2021
2022-03-30 English
Form 10-Q/T fiscal year transition report
Report Publication Announcement Classification · 98% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' filed under Israeli regulations, referencing a 'Form 10-Q/T fiscal year transition report' and attaching a PDF file named 'Oramed_Form_10-QT_2021_-_March_30_2022_isa.pdf'. A Form 10-Q is the standard SEC filing for quarterly financial reports. Since this document is an announcement *about* the filing, referencing the attached report, and the content is short (1961 chars), it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) itself. The date reported is 31/03/2022, consistent with a periodic filing.
2022-03-30 English
TRANSITION REPORT
Regulatory Filings
2022-03-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.